Q3 2023 Financial Highlights
MediMobility Organ Transport Overview
Largest dedicated air transporter of
human organs for transplant,
providing end-to-end multi-modal
solution incorporating rotorcraft, fixed-
wing aircraft, and ground vehicles
Medical missions utilize the same
aircraft that service passenger flights,
with demand typically occurring at
night, complementing consumer
demand during the day and providing
more hours for aircraft operators to
amortize their fixed costs
Fixed pricing model per trip enables
predictable flight profit and allows for
fuel cost pass-through
Organ transport represents a clear
use case for future drone or EVA
adoption, particularly given necessary
infrastructure and landing zones are
already in place at many hospitals
Key Value Proposition
Attractive, Growing
End Market
Non-cyclical, B2B
revenue with limited
marketing and strong
end market growth
MediMobility Organ Transport
Trailing Twelve Month Revenues
($ in mm)
$116
$103
$86
$72
$60
$42
Improves Patient
$26
CIT
TRANSPLANT
Shorter transport time
results in improved
organ quality and
higher success rates
$15
$3
$4
$5
$6
Outcomes
Air M
Low-Cost Provider
Vast operator network
provides customers
appropriate aircraft for
each mission with
competitive pricing
Complements
Consumer Business
Fleet commonality
increases utilization of
aircraft otherwise
idle at night
Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23
Organ Transplants in the US(1)
Heart,
Liver, and
Lung
~43K
Organs
Transplanted in
2022
Kidney &
Other
Note: Definition of all non-GAAP numbers and reconciliation to GAAP numbers are provided in the Appendix of this presentation
1.
Source: United Network for Organ Sharing (UNOS) Data and Transplant Statistics. Blade primarily services the Heart, Liver, and Lung segment of the organ logistics market
BLADE
19View entire presentation